<DOC>
	<DOCNO>NCT03008161</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple dos NPT088 patient mild moderate probable Alzheimer 's Disease . The study also evaluate pharmacokinetics , immunogenicity exploratory pharmacodynamic characteristic multiple dos NPT088 .</brief_summary>
	<brief_title>Multiple Dose Safety Study NPT088 Patients With Mild Moderate Probable Alzheimer 's Disease</brief_title>
	<detailed_description>This study multicenter Phase 1 , randomize , double-blind , placebo-controlled , multiple-dose , dose-escalation safety tolerability study NPT088 placebo patient Probable AD MMSE score 18-27 . Enrolled patient receive intravenous infusion NPT088 placebo month six month study . Four dose cohort plan first two cohort enrol 9 patient ( 6 NPT088 : 3 placebo ) final two cohort enrol 24 patient ( 16 NPT088 : 8 placebo ) total 66 patient ( 44 NPT088 : 22 placebo ) .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>For enrollment study , participant must 50 85 year age , inclusive Mini Mental State Examination ( MMSE ) score 1827 ( inclusive ) Modified Hachinski Score less equal 4 diagnosis Probable Alzheimer 's Disease ( AD ) accord consensus criterion define National Institute AgingAlzheimer 's Association work group Clinical Dementia Rating Scale ( CDR ) 0.5 1.0 , memory box score equal great 0.5 positive florbetapir positron emission tomography ( PET ) amyloid scan consent apolipoprotein E ( ApoE ) genotyping willing undergo repeat Magnetic Resonance Imaging ( MRI ) PET image stable dos allow medication least 30 day prior Screening . Concurrent treatment cholinesterase inhibitor and/or memantine allow good healthy apart clinical diagnosis AD dedicate Caregiver provide care least 4 hour day 4 day week provide inform consent participation For enrollment study , participant must NOT : history , screen MRI indicative significant brain abnormality major medical illness unstable medical condition opinion Investigator reason may interfere participant ability comply study procedure abide study restriction ability interpret safety data reside nursing home need 24hour care supervision take excluded medication exclusionary value Screening blood urine sample treat immunomodulators treat AD participate investigational drug device study within 90 day know allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GAIM</keyword>
	<keyword>amyloid</keyword>
	<keyword>anti-aBeta</keyword>
	<keyword>anti-tau</keyword>
</DOC>